The E2F7 antibody is a crucial tool for studying the E2F transcription factor family, particularly E2F7. a member of the atypical E2F subgroup (E2F7 and E2F8). Unlike classical E2Fs (E2F1-6), which regulate cell cycle progression, E2F7 functions as a transcriptional repressor involved in cell cycle exit, DNA damage response, and differentiation. It lacks a dimerization domain and binds DNA independently, often antagonizing pro-proliferative E2Fs to maintain genomic stability. E2F7 is overexpressed in various cancers, where it may promote tumorigenesis by enabling uncontrolled cell division or conferring therapy resistance.
Antibodies targeting E2F7 enable researchers to detect and quantify its expression, localization, and interactions via techniques like Western blotting, immunofluorescence, and chromatin immunoprecipitation. These reagents are essential for exploring E2F7's dual roles in normal physiology (e.g., embryonic development, tissue homeostasis) and disease contexts. Recent studies highlight its involvement in cancer progression, metabolic reprogramming, and senescence, making E2F7 a potential therapeutic target. Validated antibodies with high specificity are critical, as E2F7 shares structural homology with E2F8. Commercial antibodies are typically raised against unique epitopes in its N-terminal or central regions. Ongoing research using these tools aims to clarify E2F7's context-dependent functions and regulatory networks.